Cargando…

Efficacy and Safety of Perampanel in Children with Drug-Resistant Focal-Onset Seizures: A Retrospective Review

Background: Epilepsy is one of the most common neurological disorders. Existing antiseizure medications (ASMs) are still unable to control seizures in one-third of these patients, making the discovery of antiseizure therapies with novel mechanisms of action a necessity. Aim of the Study: This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elmardenly, Ahmed, Aljehani, Zekra, Tamim, Abdullah, Alyazidi, Anas, Muthaffar, Osama
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297347/ https://www.ncbi.nlm.nih.gov/pubmed/37371302 http://dx.doi.org/10.3390/children10061071

Ejemplares similares

The efficacy and safety of adjunctive perampanel for the treatment of refractory focal‐onset seizures in patients with epilepsy: A meta‐analysis
por: Li, Yiming, et al.
Publicado: (2022)

The efficacy of non-fasting ketogenic diet protocol in the management of intractable epilepsy in pediatric patients: a single center study from Saudi Arabia
por: Alameen Ali, Hayat, et al.
Publicado: (2022)

First add‐on perampanel for focal‐onset seizures: An open‐label, prospective study
por: Kim, Ji Hyun, et al.
Publicado: (2019)

Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study
por: Zhang, Ranran, et al.
Publicado: (2021)

An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients
por: Dozières-Puyravel, Blandine, et al.
Publicado: (2019)

Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability
por: Schulze-Bonhage, Andreas, et al.
Publicado: (2015)

Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study
por: Ma, Haiyan, et al.
Publicado: (2023)

Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study
por: Gao, Lehong, et al.
Publicado: (2023)

Case Report: Detailed Clinical Course and Management Plan for Status Epilepticus Pediatric Patient with Resected Choroid Plexus Papilloma: A Case Report and a Single Center Experience
por: Muthaffar, Osama, et al.
Publicado: (2022)

A retrospective, real‐world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience
por: Chinvarun, Yotin
Publicado: (2021)

Clinical efficacy of perampanel for partial-onset and primary generalized tonic–clonic seizures
por: Besag, Frank MC, et al.
Publicado: (2016)

Perampanel as First Add-On Therapy in Patients with Focal-Onset Seizures in the FAME Trial: Post hoc Analyses of Efficacy and Safety Related to Maintenance Dose and Background Antiepileptic Drug Therapy
por: Kim, Ji Hyun, et al.
Publicado: (2022)

Profile of perampanel and its potential in the treatment of partial onset seizures
por: Rheims, Sylvain, et al.
Publicado: (2013)

Perampanel as First Adjunctive Treatment in Patients with Focal-Onset Seizures in the FAME Study: Post hoc Analyses of Dose-Related Efficacy, Safety and Clinical Factors Associated with Response
por: Kim, Dong Wook, et al.
Publicado: (2022)

Efficacy of perampanel as an adjunctive therapy in pediatric focal epilepsy
por: Zhang, Wei-Ran, et al.
Publicado: (2023)

Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
por: Kwan, Patrick, et al.
Publicado: (2017)

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
por: Fogarasi, Andras, et al.
Publicado: (2020)

Efficacy and safety of perampanel monotherapy in patients with focal‐onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: The open‐label Study 342 (FREEDOM Study)
por: Yamamoto, Takamichi, et al.
Publicado: (2020)

Cognitive effects of adjunctive perampanel for partial‐onset seizures: A randomized trial
por: Meador, Kimford J., et al.
Publicado: (2016)

Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307
por: Krauss, Gregory L, et al.
Publicado: (2014)

Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective
por: Hu, Yani, et al.
Publicado: (2022)

Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy
por: Hsu, Warrington W. Q., et al.
Publicado: (2013)

Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures
por: Vazquez, Blanca, et al.
Publicado: (2015)

Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of phase III double‐blind and open‐label extension studies
por: Weiping, Liao, et al.
Publicado: (2020)

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India
por: Mehndiratta, Man M., et al.
Publicado: (2021)

Insight into Genetic Mutations of SZT2: Is It a Syndrome?
por: Muthaffar, Osama Y., et al.
Publicado: (2023)

Erratum to: Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy
por: Hsu, Warrington W. Q., et al.
Publicado: (2013)

Perampanel-Induced, New-Onset Thrombocytopenia in a Patient With Refractory Seizures: A Case Report
por: Almuhanna, Rakan A, et al.
Publicado: (2023)

Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double‐blind, phase III studies
por: Steinhoff, Bernhard J., et al.
Publicado: (2020)

Computational modelling of micro-seizures and focal seizure onset
por: Wang, Yujiang, et al.
Publicado: (2013)

Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial‐onset seizures: pooled analysis of clinical trials
por: Majid, Oneeb, et al.
Publicado: (2016)

Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
por: Zhang, Donger, et al.
Publicado: (2021)

Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Perampanel for focal epilepsy: insights from early clinical experience
por: Trinka, E., et al.
Publicado: (2015)

Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel
por: Dirani, Maya, et al.
Publicado: (2014)

Seizure remission and improvement of neurological function in sialidosis with perampanel therapy
por: Hu, Su-Ching, et al.
Publicado: (2018)

Assessment of the long‐term efficacy and safety of adjunctive perampanel in tonic‐clonic seizures: Analysis of four open‐label extension studies
por: Rektor, Ivan, et al.
Publicado: (2020)

Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy
por: Yi, Jia-Qin, et al.
Publicado: (2023)

Verbal fluency functional magnetic resonance imaging detects anti‐seizure effects and affective side effects of perampanel in people with focal epilepsy
por: Xiao, Fenglai, et al.
Publicado: (2023)

Brivaracetam: a novel antiepileptic drug for focal-onset seizures
por: Stephen, Linda J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_r0b6e8vnq7njgnjthdv77h447c